N/A N=53 Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Fulfillment of Bath Ankylosing Spondylitis Disease Activity Index 50 Response (BASDAI50) — 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease
Parkinson Disease
Primary: Change in the MDS-UPDRS Tremor Subscore — 0.25; 0.27 score on a scale — p=0.5
N/A N=506 Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c) — 8.29; 8.59; 8.32; 8.57 percent — p=.0493
Phase 2 N=22 Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
Nonallergic Irritant Rhinitis
Primary: Change in Total Symptom Score — -5; 2 score on a scale
Phase 4 N=165 Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Type 2 Diabetes Mellitus
Primary: The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment — -0.09; -0.44; 0.84 % of HbA1c — p=0.0036
Phase 2 N=155 A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups — 73; 81; 14; 15 Adverse Events
N/A N=9 Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation
Schizophrenia · Schizoaffective Disorder
Primary: Change in Working Memory Function — -7.28; -5.9 % change in Working Memory Task Accuracy — p=.849
N/A N=1,302 The Life STORRIED Study
Opioid Dependence · Communication · Risk Behavior
Primary: Risk Awareness and Recall — 118; 129 Participants
Phase 2 N=57 Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
HCV Infection
Primary: Area Under the Plasma Concentration-Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of EBR at Steady State — 2.41; 2.79; 1.71; 3.15 µM*hr
Phase 3 N=123 (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission — 76.7; 88.2; 92.0; 96.8 percentage of participants
Phase 2 N=5 Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 29.00; 26.20 score on a scale — p=.20
Phase 4 N=26 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
Alcohol Withdrawal
Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale
Phase 3 N=941 Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Extreme Prematurity
Primary: Number of Participants With Death or Severe Neurodevelopmental Impairment (NDI) at 22-26 Months Corrected Age — 94; 97 Participants — p=0.05
N/A N=314 Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Breast Cancer
Primary: Number of Participants With Local Recurrence in Breast — 6 Participants
Phase 2 N=51 A Study of E7080 in Subjects With Advanced Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100.0; 82.4; 52.9; 2.0 Percentage of participants